New trial
Phase II Obinutuzumab CD20-targeted mAb Trial in Relapsed or Refractory Follicular Lymphoma
- Trial ID
- NCT03269669 on ClinicalTrials.gov
- Cancer type
- Follicular Lymphoma
- Location
- 431 Locations
- Published in
- New in Oncology - June 16, 2025
This randomized Phase II trial by the National Cancer Institute compares obinutuzumab used alone or combined with umbralisib, lenalidomide, or standard chemotherapy to treat patients with grade I–IIIa relapsed or refractory follicular lymphoma. The study aims to identify the most effective immunotherapy or chemo-immunotherapy regimen.
More in lymphoma
-
Trial result · Oct 22, 2026 · NCT04245839
Liso-cel (CD19 CAR-T) Delivers 100% CR/ORR With Minimal CRS/Neurotoxicity in Japanese R/R FL -
Trial result · Oct 22, 2026 · NCT05800366
Glofitamab (CD3×CD20) + pola-R-CHP (CD79b ADC + anti-CD20 chemoimmunotherapy) drives 95% CR and 95% 24‑mo PFS in high-risk 1L DLBCL -
Trial result · Oct 15, 2026 · NCT03618550
Pembrolizumab-GVD followed by autologous transplantation shows 91% five-year PFS in relapsed/refractory classical Hodgkin lymphoma -
Trial result · Oct 15, 2026 · NCT03598608
Favezelimab (anti–LAG-3) + pembrolizumab (PD-1) reports 83% ORR in PD-1–naive R/R cHL; development discontinued -
Trial result · Oct 1, 2026
Mosunetuzumab (CD20xCD3 bispecific) + response-adapted polatuzumab vedotin (CD79b ADC) drives 86% PET-CR and 89% 2y PFS in untreated indolent NHL